The move could pit regulators’ caution and need for trust against the urgency of preventing infection and death now. On Tuesday, regulators recommended pausing the rollout of Johnson & Johnson ’s Covid-19 vaccine out of “an abundance of caution” after six out of nearly 7 million recipients developed dangerous